Inactive Instrument

Wintac Limited

524758

INE812C01016

Wintac Limited Appoints K. M. Ganga and K. Paranjothy as Additional Directors

July 27, 2017 at 01:08 pm IST

The Board of Directors of the Wintac Limited at their meeting held on July 27, 2017, appointed Ms. K. M. Ganga and Dr. K. Paranjothy as Additional Directors on the Board. Ms. K. M. Ganga and Dr. K. Paranjothy are also the Independent Directors on the board.

Latest news about Wintac Limited

Somerset Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2023	10/23/10	CI
Wintac Limited Reports Earnings Results for the Full Year Ended March 31, 2022	11/22/11	CI
Wintac Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	12/20/12	CI
Wintac Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	07/20/07	CI
Wintac Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	22/20/22	CI
Wintac Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	04/20/04	CI
Wintac Limited Appoints S. Nanthitha as Additional Director	04/20/04	CI
Wintac Limited Announces Resignation of Ms. K. M. Ganga as Independent Director	27/20/27	CI
Wintac Limited Reports Earnings Results for the Second Quarter Ended September 30, 2019	13/19/13	CI
Wintac Limited Reports Earnings Results for the First Quarter Ended June 30, 2019	12/19/12	CI
Wintac Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	23/19/23	CI
Par Formulations Pvt Ltd cancelled the acquisition of Pharmaceutical Business from Wintac Limited.	27/19/27	CI
Wintac Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2018	11/19/11	CI
Wintac Ltd Announces Unaudited Standalone Financial Results for the Second Quarter and Six Months Ended September 30, 2018	12/18/12	CI
Wintac Ltd. Reports Unaudited Earnings Results for the First Quarter Ended June 30, 2018	07/18/07	CI
Wintac Limited Announces Resignation of B. R. Arun Eashwar as Independent Director	29/18/29	CI
Wintac Limited Announces Audited Earnings Results for the Fourth Quarter and Year Ended March 31, 2018	23/18/23	CI
Wintac Limited Appoints R.A.Thirumoorti as Additional Director	23/18/23	CI
Par Formulations Pvt Ltd agreed to acquire Pharmaceutical Business from Wintac Limited for $15.3 million.	26/18/26	CI
VEEGO PHARMA, LLC made a proposal to acquire remaining 45% stake in Wintac Limited from public shareholders for approximately INR 990 million.	23/18/23	CI
Wintac Limited Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017	10/18/10	CI
Wintac Ltd Announces Unaudited Standalone Financial Results for the Second Quarter and Six Months Ended September 30, 2017	06/17/06	CI
Wintac Ltd. Reports Unaudited Earnings Results for the First Quarter Ended June 30, 2017	11/17/11	CI
Wintac Limited Announces the Resignation of Independent Directors	11/17/11	CI
Wintac Limited Appoints K. M. Ganga and K. Paranjothy as Additional Directors	27/17/27	CI

Chart Wintac Limited

Duration

Period

More charts

Company Profile

Wintac Limited is an India-based company, which is engaged in the formulations business. The Company is involved in formulation sales, manufacturing charges and formulation development. Its products are classified under categories, including injectable and ophthalmic. Its ophthalmic product range includes Timolol Maleate Eye Drops, Atropine Eye Drops, Fluorometholone Eye Drops, Olopatadine Eye Drops, Chloramphenicol Eye Drops, Diclofenac Eye Drops, Ketorolac Tromethamine Eye Drops and Bromfenac Eye Drops. Its injectable product range includes Diclofenac Injection, Pheniramine Maleate Injection, Iron Sucrose Injection, Pentoxifylline Injection, Atropine Injection, Hyoscine Butyl Bromide Injection, Ondansetron Injection, Metoclopramide Injection, Tramadol Injection, Analgin Injection, Gentamicin Sulphate Injection and Levofloxacin Injection. The Company carries out formulation development activities in the export market, including the United States, Canada, Australia and Europe.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+54.07%	81TCr
NOVO NORDISK A/S	+38.18%	62TCr
JOHNSON & JOHNSON	-7.05%	35TCr
MERCK & CO., INC.	+15.44%	32TCr
ABBVIE INC.	+5.72%	29TCr
ASTRAZENECA PLC	+14.26%	24TCr
ROCHE HOLDING AG	-1.55%	22TCr
NOVARTIS AG	+13.67%	22TCr
AMGEN INC.	+7.42%	17TCr

Other Pharmaceuticals